Usnadnění a zpřesnění imunofenotypové diagnostiky a definice molekulární remise dětských AML a MDS definice role genu WT1 jako markeru MRN ověření využití valproové kyseliny v léčbě a identifikace genetických změn ve vývoji (pre)leukemického klonu. (cs)
Our project is focused (in accordance with the technical possibilities, numbers of patients in the Czech Republic, previous focus of our research and the individual working goals of EuGESMA) on the ed scientific problems concerning childhood AML and MDS. We will define and test a newly modified immunophenotypic diagnostic and stratification of childhood AML and MDS. We will test the potential of polychromatic flow cytometry for a new definition of molecular remission and residual disease follow-up. We will determine the role of expression quantification of WT1 gene and its isoforms in the diagnosis and follow-up of childhood AML and MDS. In vitro we will apply valproic acid as a new treatment modality in the cases of AML1/ETO-positive AML. In cases of secAL, we will search for so-far unknown genetic aberrations. We will contribute to expression profiling studies in childhood AML. (en)